FDA expectations for preclinical drug testing as part of new drug applications are growing. That promises good business for Exton, Pa.-based Absorption Systems, company officials say. The firm develops and performs assays to predict the absorption, distribution, metabolism, and excretion profiles of small molecules in humans.
"I don't have numbers on how it will impact the business, but it will be dramatic," says company president, CEO, and cofounder Patrick Dentinger. He was referring specifically to emerging Food and Drug Administration recommendations that drug developers study how drugs affect each other's activities through their interactions with the body's transport proteins.
The company is well positioned to compete in a new market for assays, thanks to these recommendations, Dentinger says. The guidelines prompted "an uptick in clients who came to us" ...
